Substrate recognition strategy for butulinum neurotoxin serotype A

Nature

Volumn 432, Issue 7019, 2004, Pages 925-929

  Breidenbach, Mark A ^a   Brunger, Axel T ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CATALYSIS; DISEASE CONTROL; ENZYMES; HYDROLYSIS; PROTEINS;

CAUSATIVE AGENTS; CLOSTRIDAL NEUROTOXINS (CNT); EXOSITES;

NEURAL NETWORKS;

BACTERIAL ENZYME; BOTULINUM TOXIN A; METALLOPROTEINASE;

MEDICINE;

ARTICLE; CATALYSIS; ENZYME BINDING; ENZYME KINETICS; ENZYME SUBSTRATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE;

BINDING SITES; BOTULINUM TOXIN TYPE A; CATALYSIS; CLOSTRIDIUM BOTULINUM; ENDOPEPTIDASES; HUMANS; HYDROLYSIS; KINETICS; MEMBRANE PROTEINS; MODELS, MOLECULAR; MUTATION; NERVE TISSUE PROTEINS; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 11144341950     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03123     Document Type: Article

References (30)

1. Humeau, Y., Doussau, F., Grant, N. J. & Poulain, B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82, 427-446 (2000).
2. Dolly, J. O., Black, J., Williams, R. S. & Melling, J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 307, 457-460 (1984).
3. Schiavo, G. et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832-835 (1992).
4. 2+ and drives membrane fusion. Cell 97, 165-174 (1999).
5. Söllner, T. et al., SNAP receptors implicated in vesicle targeting and fusion. Nature 362, 318-324 (1993).
6. Pellegrini, L. L., O'Connor, V., Lottspeich, F. & Betz, H. Clostridial neurotoxins compromise the stability of a low energy SNARE complex mediating NSF activation of synaptic vesicle fusion. EMBO J. 14, 4705-4713 (1995).
7. Xu, T., Binz, T., Niemann, H. & Neher, E. Multiple kinetic components of exocytosis distinguished by neurotoxin sensitivity. Nature Neurosci. 1, 192-200 (1998).
8. Rossetto, O. et al. SNARE motif and neurotoxins. Nature 372, 415-416 (1994).
9. Pellizzari, R. et al. Structural determinants of the specificity for synaptic vesicle-associated membrane protein/synaptobrevin of tetanus and botulinum type B and G neurotoxins. J. Biol. Chem. 271, 20353-20358 (1996).
10. Cornille, F. et al. Cooperative exosite-dependent cleavage of synaptobrevin by tetanus toxin light chain. J. Biol. Chem. 272, 3459-3464 (1997).
11. Holden, H. M., Tronrud, D. E., Monzingo, A. F., Weaver, L. H. & Matthews, B. W. Slow- and fast-binding inhibitors of thermolysin display different modes of binding: crystallographic analysis of extended phosphonamidate transition-state analogues. Biochemistry 26, 8542-8553 (1987).
12. Lacy, D. B., Tepp, W., Cohen, A. C., DasGupta, B. R. & Stevens, R. C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nature Struct. Biol. 5, 898-902 (1998).
13. Hanson, M. A. & Stevens, R. C. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Å resolution. Nature Struct. Biol. 7, 687-692 (2000).
14. Agarwal, R., Eswaramoorthy, S., Kumaran, D., Binz, T. & Swaminathan, S. Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant glu212 → gln reveals the pivotal role of the glu212 carboxylate in the catalytic pathway. Biochemistry 43, 6637-6644 (2004).
15. Vaidyanathan, V. V. et al. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J. Neurochem. 72, 327-337 (1999).
16. Foran, P., Shone, C. C. & Dolly, J. O. Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry 33, 15365-15374 (1994).
17. Washbourne, P., Pellizzari, R., Baldini, G., Wilson, M. C. & Montecucco, C. Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis. FEBS Lett. 418, 1-5 (1997).
18. Li, L., Binz, T., Niemann, H. & Singh, B. R. Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain. Biochemistry 39, 2399-2405 (2000).
19. Binz, T., Bade, S., Rummel, A., Kollewe, A. & Alves, J. Arg(362) and Tyr(365) of the botulinum neurotoxin type A light chain are involved in transition state stabilization. Biochemistry 41, 1717-1723 (2002).
20. Brooijmans, N., Sharp, K. A. & Kuntz, I. D. Stability of macromolecular complexes. Proteins 48, 645-653 (2002).
21. Sutton, R. B., Fasshauer, D., Jahn, R. & Brunger, A. T. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 Å resolution. Nature 395, 347-353 (1998).
22. Rupp, B. & Segelke, B. Questions about the structure of the botulinum neurotoxin B light chain in complex with a target peptide. Nature Struct. Biol. 8, 663-664 (2001).
23. Sukonpan, C. et al. Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease. J. Pept. Res. 63, 181-193 (2004).
24. Schmidt, J. J. & Bostian, K. A. Proteolysis of synthetic peptides by type A botulinum neurotoxin. J. Protein Chem. 14, 703-708 (1995).
25. Fiebig, K. M., Rice, L. M., Pollock, E. & Brunger, A. T. Folding intermediates of SNARE complex assembly. Nature Struct. Biol. 6, 117-123 (1999).
26. Segelke, B., Knapp, M., Kadkhodayan, S., Balhorn, R. & Rupp, B. Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: evidence for noncanonical zinc protease activity. Proc. Natl Acad. Sci. USA 101, 6888-6893 (2004).
27. Matthews, B. W. Structural basis of the action of thermolysin and related zinc peptidases. Acc. Chem. Res. 21, 333-340 (1988).
28. Dall'Acqua, W. & Carter, P. Substrate-assisted catalysis: molecular basis and biological significance. Protein Sci. 9, 1-9 (2000).
29. Fasshauer, D., Bruns, D., Shen, B., Jahn, R. & Brunger, A. T. A structural change occurs upon binding of syntaxin to SNAP-25. J. Biol. Chem. 272, 4582-4590 (1997).
30. Debnath, A. K., Radigan, L. & Jiang, S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 42, 3203-3209 (1999).